use of ivabradine - a heart rate lowering drug, to reduce heart rate and improve blood pressure in patients with liver disease and sepsis

Effect of ivabradine on hemodynamics in cirrhotic patients with septic shock - A pilot study

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2020/07/026628

Enrollment

Registered

2020-07-16

Start date

Unknown

Completion date

Unknown

Last updated

2023-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K746- Other and unspecified cirrhosis ofliver

Interventions

Intervention1: Ivabradine: whenever patient heart rate is more than 100 and patient is requiring inotrope or vasopressor for maintaining blood pressure.Given 5mg twice a day, orally for 3 days Control

Eligibility

Inclusion criteria

Inclusion criteria: patients with Child-Pugh A or B cirrhosis with septic shock (as per sepsis 3 guidelines) and Unexplained tachycardia with a heart rate more than 100/min for more 30 minutes

Exclusion criteria

Exclusion criteria: Acute liver failure Patients with bradyarrhythmia and tachyarrythmia except sinus tachycardia Patients on terlipressin therapy CKD stage 5 Gastric residual volume or aspirate more than 500ml/6hrs Pregnant patients Patients who donâ??t give consent

Design outcomes

Primary

Measure	Time frame
reduction of heart rate with ivabdradine will increase diastolic time and cardiac filling and hence result in decrease of vasopressor requirement and will cause reversal of shock Timepoint: 28 days	—

Secondary

Measure	Time frame
incidence of renal replacement therapy, changes in lactate, need of mechanical ventilation and mortality differenceTimepoint: 24, 48, 72 hours and 28 days	—

Countries

India

Contacts

Public ContactAmal Francis Sam

ILBS

mkarora442@gmail.com8968163281

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026